Reaction time and movement time after embryonic cell implantation in Parkinson disease
- PMID: 15210522
- DOI: 10.1001/archneur.61.6.858
Reaction time and movement time after embryonic cell implantation in Parkinson disease
Abstract
Background: Embryonic nigral cell implants are a novel treatment for Parkinson disease (PD). Reaction time (RT) and movement time (MT) analysis, validated quantitative measures of premovement neural processing and motor execution, can be used as objective physiological markers of motor performance in PD.
Objectives: To gauge the change in motor performance in patients with PD who received implants, and to determine whether the physiological findings correlate with clinical outcome measures after transplantation.
Design: Double-blind, placebo-controlled trial. Patients Forty patients with levodopa-responsive, Hoehn and Yahr stage III or greater PD.
Interventions: Random assignment to embryonic tissue implants or placebo (sham) operation.
Main outcome measures: Combined RT + MT scores measured preoperatively and at 4 and 12 months postoperatively in the "off" state.
Results: The difference in mean RT + MT scores between the sham and implant groups was statistically significant (P =.005) and was greatest in those 60 years or older (P =.003). Changes correlated with Unified Parkinson's Disease Rating Scale off scores at 4 (r = 0.87, P =.001) and 12 (r = 0.75, P =.01) months in those younger than 60 years. There was a significant deterioration in the sham surgery group at 12 months (P =.03) that was thought to be due to worsening in subjects 60 years and older (P<.001).
Conclusions: The physiological measures detected significant changes in patients undergoing embryonic nigral cell implants and correlated directly with clinical outcome measures. Comprehensive analyses of RT paradigms can document subtle changes in motor performance over time, making them useful outcome measures in therapeutic trials of PD. These findings support further research into nigral cell implantation for PD.
Comment in
-
Positive potential of fetal nigral implants for Parkinson disease.Arch Neurol. 2004 Jun;61(6):837-8. doi: 10.1001/archneur.61.6.837. Arch Neurol. 2004. PMID: 15210519 No abstract available.
Similar articles
-
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.Arch Neurol. 2005 Feb;62(2):241-8. doi: 10.1001/archneur.62.2.241. Arch Neurol. 2005. PMID: 15710852 Clinical Trial.
-
Transplantation of embryonic dopamine neurons for severe Parkinson's disease.N Engl J Med. 2001 Mar 8;344(10):710-9. doi: 10.1056/NEJM200103083441002. N Engl J Med. 2001. PMID: 11236774 Clinical Trial.
-
Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial.Arch Gen Psychiatry. 2004 Apr;61(4):412-20. doi: 10.1001/archpsyc.61.4.412. Arch Gen Psychiatry. 2004. PMID: 15066900 Clinical Trial.
-
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021. Clin Ther. 2007. PMID: 18035186 Review.
-
[Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system].Zentralbl Neurochir. 1995;56(4):153-60. Zentralbl Neurochir. 1995. PMID: 8571693 Review. German.
Cited by
-
Saccadic latency distributions in Parkinson's disease and the effects of L-dopa.Exp Brain Res. 2006 Sep;174(1):7-18. doi: 10.1007/s00221-006-0412-z. Epub 2006 Mar 17. Exp Brain Res. 2006. PMID: 16544135 Free PMC article.
-
Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives.Primate Biol. 2017 Oct 11;4(2):185-213. doi: 10.5194/pb-4-185-2017. eCollection 2017. Primate Biol. 2017. PMID: 32110706 Free PMC article. Review.
-
Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.Pharmaceuticals (Basel). 2021 Jul 25;14(8):717. doi: 10.3390/ph14080717. Pharmaceuticals (Basel). 2021. PMID: 34451813 Free PMC article. Review.
-
Parkinson's disease: fetal cell or stem cell-derived treatments.BMJ Clin Evid. 2015 Apr 21;2015:1203. BMJ Clin Evid. 2015. PMID: 25898159 Free PMC article.
-
Placebo effects in trials evaluating 12 selected minimally invasive interventions: a systematic review and meta-analysis.BMJ Open. 2015 Jan 30;5(1):e007331. doi: 10.1136/bmjopen-2014-007331. BMJ Open. 2015. PMID: 25636794 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical